HNGE stock forecast, quote, news & analysis
Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain... Show more
Hinge Health (HNGE) Stock Analysis: AI Automation Fuels Record Revenue and a $105M GI Expansion
Key Takeaways
- HNGE shares have climbed roughly 9% over the trailing 30 days, holding near 52-week highs after a powerful 2026 run.
- Second-quarter 2026 revenue rose 53% year over year to $213 million, while operating margin expanded to 29% from 19%.
- The company signed a definitive agreement to acquire Cylinder Health for $105 million in cash, adding gastrointestinal care to its platform.
- Full-year 2026 revenue guidance was raised to $856 million–$860 million, with non-GAAP operating income guided to $236 million–$244 million.
- Analyst sentiment has turned constructive, with several firms issuing Buy ratings and raising price targets.
Current Market Snapshot
Hinge Health shares recently traded near $97.95, within striking distance of their 52-week highs and up roughly 9% over the prior 30 days. That short-term move extends a substantially larger year-to-date advance, reflecting strong demand for the stock after a record quarterly report and an upward revision to full-year guidance. The stock's elevated price-to-earnings multiple—in the range of roughly 70 times—signals that investors are pricing in continued rapid growth and margin expansion rather than current profitability alone.
Hinge Health (HNGE) Business Overview and Competitive Position
Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) health, covering the spectrum from acute injury and chronic pain to post-surgical rehabilitation. Its core platform, built around AI-powered motion-tracking technology and the Enso wearable for non-addictive pain relief, pairs software with a care team of licensed physical therapists, physicians, and health coaches. Founded in 2014 and headquartered in San Francisco, the company serves employers and health plans and has expanded into adjacent care categories, including migraine and gastrointestinal health. Its strategy centers on automating care delivery to improve member outcomes while lowering costs for clients, positioning Hinge Health as one of the most prominent names in virtual-first MSK care.
Recent Developments Driving HNGE
The most significant recent catalyst was Hinge Health's second-quarter 2026 report, which showed revenue of $213 million—up 53% year over year and above the company's prior guidance range. Operating income more than doubled to $62 million, gross margin reached 87%, and free cash flow climbed to $100 million from $33 million a year earlier. Last-twelve-month calculated billings rose 52% to $862 million, a leading indicator management highlights for future revenue growth.
Alongside the results, Hinge Health raised its 2026 outlook, citing durable improvements in member engagement, or "yield." The company now expects full-year revenue of $856 million to $860 million and non-GAAP operating income of $236 million to $244 million. Management also announced a $300 million share-repurchase authorization after repurchasing roughly 480,000 shares for $26 million during the quarter.
The company's expansion strategy has drawn particular attention. Hinge Health signed a definitive agreement to acquire Cylinder Health, a virtual-first gastrointestinal care provider with nearly 100 clients covering about 2 million lives, for $105 million in cash. The deal is expected to contribute roughly $7 million to $8 million of revenue in 2026, with broader scaling anticipated in 2027 and beyond. Separately, the company's newer Migraine Care Program has enrolled more than 450 clients covering over 5 million lives. Analyst activity has reflected this momentum, with Bank of America initiating coverage with a Buy rating and a $110 target, while Stifel and Needham raised their price targets to $115.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently among the most relevant and highest-performing on the platform. Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most applicable strategies appear in this featured section. The bots vary widely in approach, timeframe, and performance metrics, allowing traders to evaluate options that align with different objectives and risk profiles. For those seeking data-driven tools to monitor momentum across names like HNGE, exploring the Trending AI Robots section can provide an additional layer of market insight.
2026 Outlook and What Investors Should Watch
Looking ahead, investors will likely focus on the third-quarter 2026 report, where management has guided to revenue of $223 million to $225 million—roughly 45% growth at the midpoint. Sustained yield improvements, growth in eligible lives, and average selling price per member remain the key drivers of the company's billings trajectory.
The Cylinder Health integration is another area to monitor, with completion targeted by summer 2027 and a broader gastrointestinal rollout planned for 2027. Because the business is expected to operate at a loss initially, execution on integration and its path toward Hinge Health's profitability profile will be closely watched. Broader themes—including employer and health-plan budget cycles, competition in virtual care, and healthcare spending conditions—also matter for the company's land-and-expand model. At current valuation levels, continued delivery on growth and margin targets will be central to how the market assesses the stock's premium.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for HNGE shows an upward move is likely
HNGE's Aroon Indicator triggered a bullish signal on October 22, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 63 similar instances where the Aroon Indicator showed a similar pattern. In 54 of the 63 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on HNGE as a result. In 18 of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for HNGE just turned positive on October 01, 2026. Looking at past instances where HNGE's MACD turned positive, the stock continued to rise in 8 of 10 cases over the following month. The odds of a continued upward trend are 80%.
Following a +7.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 79 of 93 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for HNGE moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 5 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
HNGE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (26.248) is slightly higher than the industry average of (3.981). P/E Ratio (13.559) is within average values for comparable stocks, (13.628). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry